66. IgA腎症 IgA nephropathy Clinical trials / Disease details
臨床試験数 : 255 / 薬物数 : 255 - (DrugBank : 79) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 137
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00396721 (ClinicalTrials.gov) | January 2006 | 3/11/2006 | Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy | Pilot Trial of Treatment of Poor-Prognosis IgA Nephropathy With Low Exposure to Sirolimus. | Glomerulonephritis, IGA;Nephropathy, IGA;IGA Nephropathy | Drug: ACE inhibitor + statin;Drug: Sirolimus (study drug)+ACE inhibitor + statin | Josep m Cruzado | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | 18 Years | 70 Years | Both | 23 | Phase 2 | Spain |
2 | EUCTR2005-002610-37-ES (EUCTR) | 05/12/2005 | 30/09/2005 | PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS.Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas de sirolimus | PILOT TRIAL OF TREATMENT OF POOR-PROGNOSIS IgA NEPHROPATHY WITH LOW EXPOSURE TO SIROLIMUS.Ensayo clínico piloto de tratamiento de la nefropatía IgA con factores de mal pronóstico con dosis bajas de sirolimus | To test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy. | Trade Name: RAPAMUNE Product Name: SIROLIMUS INN or Proposed INN: Sirolimus Trade Name: RAPAMUNE Product Name: SIROLIMUS INN or Proposed INN: Sirolimus Trade Name: RAPAMUNE Product Name: SIROLIMUS INN or Proposed INN: Sirolimus | NEPHROLOGY DEPARTMENT (HOSPITAL UNIVERSITARY OF BELLVITGE) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Spain |